Compare Stocks: EDSA, TNXP, ARCT, and KRRO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$8.24 +1.2%	$6.79	$5.50 ▼ $24.17	$234.04M	2.39	482,648 shs	248,680 shs
EDSA Edesa Biotech	$5.73 +1.4%	$6.29	$0.72 ▼ $20.32	$55.21M	1.08	1.92 million shs	41,052 shs
KRRO Korro Bio	$12.80 -2.6%	$12.44	$5.20 ▼ $55.89	$188.45M	3.04	198,045 shs	27,112 shs
TNXP Tonix Pharmaceuticals	$12.71 +0.4%	$11.71	$9.40 ▼ $39.45	$217.98M	1.69	459,819 shs	99,411 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	-1.09%	+15.46%	+34.55%	+21.67%	-58.21%
EDSA Edesa Biotech	+5.61%	+7.82%	-14.39%	-52.72%	+153.36%
KRRO Korro Bio	-1.05%	-2.59%	+7.27%	+43.69%	-35.14%
TNXP Tonix Pharmaceuticals	-0.39%	+0.56%	+1.85%	-7.66%	-75.39%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$8.24 +1.2%	$6.79	$5.50 ▼ $24.17	$234.04M	2.39	482,648 shs	248,680 shs
EDSA Edesa Biotech	$5.73 +1.4%	$6.29	$0.72 ▼ $20.32	$55.21M	1.08	1.92 million shs	41,052 shs
KRRO Korro Bio	$12.80 -2.6%	$12.44	$5.20 ▼ $55.89	$188.45M	3.04	198,045 shs	27,112 shs
TNXP Tonix Pharmaceuticals	$12.71 +0.4%	$11.71	$9.40 ▼ $39.45	$217.98M	1.69	459,819 shs	99,411 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	-1.09%	+15.46%	+34.55%	+21.67%	-58.21%
EDSA Edesa Biotech	+5.61%	+7.82%	-14.39%	-52.72%	+153.36%
KRRO Korro Bio	-1.05%	-2.59%	+7.27%	+43.69%	-35.14%
TNXP Tonix Pharmaceuticals	-0.39%	+0.56%	+1.85%	-7.66%	-75.39%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	2.64	Moderate Buy	$24.25	197.91% Upside
EDSA Edesa Biotech	2.67	Moderate Buy	$5.00	-11.50% Downside
KRRO Korro Bio	2.92	Moderate Buy	$16.71	27.20% Upside
TNXP Tonix Pharmaceuticals	3.00	Buy	$24.50	93.52% Upside

Current Analyst Ratings Breakdown

Latest EDSA, TNXP, ARCT, and KRRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/10/2026	TNXP Tonix Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$27.00
7/28/2026	TNXP Tonix Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	ARCT Arcturus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/13/2026	TNXP Tonix Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/6/2026	KRRO Korro Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/29/2026	EDSA Edesa Biotech	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
6/24/2026	TNXP Tonix Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$26.00
6/24/2026	EDSA Edesa Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	TNXP Tonix Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
5/29/2026	KRRO Korro Bio	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
5/19/2026	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$20.00 ➝ $15.00

(Data available from 8/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$82.03M	2.82	N/A	N/A	$7.53 per share	1.08
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	$0.45 per share	N/A
KRRO Korro Bio	$2.38M	81.23	N/A	N/A	$5.46 per share	2.41
TNXP Tonix Pharmaceuticals	$13.11M	16.56	N/A	N/A	$19.17 per share	0.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$65.78M	-$3.31	N/A	N/A	N/A	-317.62%	-46.54%	-36.46%	N/A
EDSA Edesa Biotech	-$7.19M	-$1.69	N/A	N/A	N/A	N/A	-560.22%	-105.74%	N/A
KRRO Korro Bio	-$117.26M	-$10.00	N/A	N/A	N/A	-1,834.48%	-114.26%	-68.57%	N/A
TNXP Tonix Pharmaceuticals	-$124.02M	-$12.94	N/A	N/A	N/A	-548.64%	-68.99%	-61.31%	N/A

Latest EDSA, TNXP, ARCT, and KRRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q3 2026	EDSA Edesa Biotech	-$0.4350	-$0.60	-$0.1650	-$0.60	N/A	N/A
8/10/2026	Q2 2026	TNXP Tonix Pharmaceuticals	-$2.64	-$2.44	+$0.20	-$2.44	$7.72 million	$13.54 million
8/6/2026	Q2 2026	ARCT Arcturus Therapeutics	-$0.9964	-$0.84	+$0.1564	-$0.84	$3.11 million	$2.96 million
8/6/2026	Q2 2026	KRRO Korro Bio	-$1.34	-$1.07	+$0.27	-$1.07	$0.21 million	$1.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	N/A
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	N/A	5.88	5.88
EDSA Edesa Biotech	N/A	2.76	2.76
KRRO Korro Bio	N/A	9.55	9.55
TNXP Tonix Pharmaceuticals	N/A	6.61	6.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
EDSA Edesa Biotech	5.50%
KRRO Korro Bio	13.18%
TNXP Tonix Pharmaceuticals	82.26%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	17.80%
EDSA Edesa Biotech	24.40%
KRRO Korro Bio	4.80%
TNXP Tonix Pharmaceuticals	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	28.42 million	23.36 million	Optionable
EDSA Edesa Biotech	20	9.63 million	7.28 million	Not Optionable
KRRO Korro Bio	70	14.73 million	14.02 million	No Data
TNXP Tonix Pharmaceuticals	50	17.15 million	16.81 million	Not Optionable

EDSA, TNXP, ARCT, and KRRO Headlines

Recent News About These Companies

Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline

August 18 at 3:00 AM | marketbeat.com

Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript

August 17 at 2:35 PM | fool.com

Tonix Pharmaceuticals Earnings Call Highlights Surging TONMYA Momentum

August 12, 2026 | theglobeandmail.com

Tonix Pharmaceuticals: Stronger-Than-Expected Tonmya Launch, Expanded Market Access, and Advancing Pipeline Underpin Buy Rating

August 11, 2026 | tipranks.com

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

August 10, 2026 | markets.businessinsider.com

Tonix outlines TNX-4800 Phase II with ~3,300 participants while scaling TONMYA to ~150 reps by September

August 10, 2026 | seekingalpha.com

Tonix Pharmaceuticals Holding C (TNXP) Q2 FY2026 earnings call transcript

August 10, 2026 | finance.yahoo.com

Penny Stocks: What Does Tonix Pharmaceuticals (NASDAQ:TNXP) Update Signal?

August 10, 2026 | kalkinemedia.comK

Tonix Pharmaceuticals Holding Corp (TNXP) (Q2 2026) Earnings Call Highlights: TONMYA Surges ...

August 10, 2026 | finance.yahoo.com

Tonix Pharmaceuticals Q2 Earnings Call Highlights

August 10, 2026 | marketbeat.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Announces Earnings Results

August 10, 2026 | marketbeat.com

Tonix Pharmaceuticals Reports Q2 Revenue of $13.5 Million

August 10, 2026 | quiverquant.comQ

Tonix Pharmaceuticals (TNXP) Expected to Announce Quarterly Earnings on Monday

August 9, 2026 | americanbankingnews.com

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

August 5, 2026 | finance.yahoo.com

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

August 5, 2026 | globenewswire.com

Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent ...

August 3, 2026 | markets.businessinsider.com

Tonix Pharmaceuticals (TNXP) Expected to Release Earnings on Monday

August 3, 2026 | marketbeat.com

Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.

August 3, 2026 | finance.yahoo.com

Tonix Pharma Advances Phase 2 Lyme Disease Vaccine Study

August 3, 2026 | tipranks.com

August 3, 2026 | globenewswire.com

Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026

July 27, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDSA, TNXP, ARCT, and KRRO Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$8.24 +0.10 (+1.17%)

As of 01:06 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Edesa Biotech NASDAQ:EDSA

$5.73 +0.08 (+1.43%)

As of 01:04 PM Eastern

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Korro Bio NASDAQ:KRRO

$12.80 -0.35 (-2.63%)

As of 01:06 PM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Tonix Pharmaceuticals NASDAQ:TNXP

$12.71 +0.05 (+0.39%)

As of 01:07 PM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EDSA, TNXP, ARCT, and KRRO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EDSA, TNXP, ARCT, and KRRO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EDSA, TNXP, ARCT, and KRRO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDSA, TNXP, ARCT, and KRRO Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

Edesa Biotech NASDAQ:EDSA

Korro Bio NASDAQ:KRRO

Tonix Pharmaceuticals NASDAQ:TNXP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EDSA, TNXP, ARCT, and KRRO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EDSA, TNXP, ARCT, and KRRO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EDSA, TNXP, ARCT, and KRRO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDSA, TNXP, ARCT, and KRRO Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

Edesa Biotech NASDAQ:EDSA

Korro Bio NASDAQ:KRRO

Tonix Pharmaceuticals NASDAQ:TNXP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools